Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians : A Systematic Review and Meta-Analysis

Zhang, Danyi ; Qiu, Jianing ; Liao, Xing ; Xiao, Yi ; Shen, Minxue ; Deng, Yaxiong LU and Jing, Danrong (2022) In Frontiers in Medicine 8.
Abstract

Background: Interleukin-17 (IL-17) monoclonal antibody drugs have been increasingly significant in the treatment of psoriasis, but it is not clear whether the efficacy is equivalent across ethnicities. Objective: To explore the differences of short-term efficacy of IL-17 inhibitors between Caucasians and Asians. Methods: The pooled log risk ratio (logRR) between the groups was estimated. The meta-regression analysis on the logRR was performed, with the proportion of Caucasian patients as the covariate. The subgroup analysis was performed by specific IL-17 inhibitors. Results: Of the 1,569 potentially relevant studies, sixteen randomized controlled trials (RCTs) were included. For the Psoriasis Area and Severity Index 75 (PASI 75)... (More)

Background: Interleukin-17 (IL-17) monoclonal antibody drugs have been increasingly significant in the treatment of psoriasis, but it is not clear whether the efficacy is equivalent across ethnicities. Objective: To explore the differences of short-term efficacy of IL-17 inhibitors between Caucasians and Asians. Methods: The pooled log risk ratio (logRR) between the groups was estimated. The meta-regression analysis on the logRR was performed, with the proportion of Caucasian patients as the covariate. The subgroup analysis was performed by specific IL-17 inhibitors. Results: Of the 1,569 potentially relevant studies, sixteen randomized controlled trials (RCTs) were included. For the Psoriasis Area and Severity Index 75 (PASI 75) response at week 12, the pooled logRR of the Asian group and the Caucasian group was 2.81 (95% CI: 2.27–3.35, p < 0.001) and 2.93 (95% CI: 2.71–3.16, p < 0.001), respectively, indicating no significant difference of efficacy between Asians and Caucasians. The meta-regression analysis did not show an association of the proportion of Caucasians with the effect size (β = 0.3203, p = 0.334). In the subgroup analysis, the comparison results of secukinumab were consistent with the main analysis. Limitations: Only the short-term efficacy was explored. The data from Asian countries were limited. Conclusions: The short-term efficacy of IL-17 inhibitors in the treatment of psoriasis has no significant difference between Caucasians and Asians. Systematic Review Registration: PROSPERO, identifier CRD42020201994, https://www.crd.york.ac.uk/prospero/.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Asian, brodalumab, Caucasian, ixekizumab, psoriasis, secukinumab
in
Frontiers in Medicine
volume
8
article number
814938
publisher
Frontiers Media S. A.
external identifiers
  • scopus:85124378533
  • pmid:35145980
ISSN
2296-858X
DOI
10.3389/fmed.2021.814938
language
English
LU publication?
yes
id
53b9f9ca-1659-4480-9a5a-44cf97c9d51d
date added to LUP
2022-12-30 13:17:53
date last changed
2024-06-24 07:42:58
@article{53b9f9ca-1659-4480-9a5a-44cf97c9d51d,
  abstract     = {{<p>Background: Interleukin-17 (IL-17) monoclonal antibody drugs have been increasingly significant in the treatment of psoriasis, but it is not clear whether the efficacy is equivalent across ethnicities. Objective: To explore the differences of short-term efficacy of IL-17 inhibitors between Caucasians and Asians. Methods: The pooled log risk ratio (logRR) between the groups was estimated. The meta-regression analysis on the logRR was performed, with the proportion of Caucasian patients as the covariate. The subgroup analysis was performed by specific IL-17 inhibitors. Results: Of the 1,569 potentially relevant studies, sixteen randomized controlled trials (RCTs) were included. For the Psoriasis Area and Severity Index 75 (PASI 75) response at week 12, the pooled logRR of the Asian group and the Caucasian group was 2.81 (95% CI: 2.27–3.35, p &lt; 0.001) and 2.93 (95% CI: 2.71–3.16, p &lt; 0.001), respectively, indicating no significant difference of efficacy between Asians and Caucasians. The meta-regression analysis did not show an association of the proportion of Caucasians with the effect size (β = 0.3203, p = 0.334). In the subgroup analysis, the comparison results of secukinumab were consistent with the main analysis. Limitations: Only the short-term efficacy was explored. The data from Asian countries were limited. Conclusions: The short-term efficacy of IL-17 inhibitors in the treatment of psoriasis has no significant difference between Caucasians and Asians. Systematic Review Registration: PROSPERO, identifier CRD42020201994, https://www.crd.york.ac.uk/prospero/.</p>}},
  author       = {{Zhang, Danyi and Qiu, Jianing and Liao, Xing and Xiao, Yi and Shen, Minxue and Deng, Yaxiong and Jing, Danrong}},
  issn         = {{2296-858X}},
  keywords     = {{Asian; brodalumab; Caucasian; ixekizumab; psoriasis; secukinumab}},
  language     = {{eng}},
  month        = {{01}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Medicine}},
  title        = {{Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians : A Systematic Review and Meta-Analysis}},
  url          = {{http://dx.doi.org/10.3389/fmed.2021.814938}},
  doi          = {{10.3389/fmed.2021.814938}},
  volume       = {{8}},
  year         = {{2022}},
}